Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: The move by France, with its fashion and luxury industries worth tens of billions of euros, comes after a similar ban by Israel in 2013, while other countries, like Italy and Spain, rely on voluntary codes of conduct to protect models. The measure is part of a campaign against anorexia by President Francois Hollande’s government. Lawmakers also made it illegal to condone anorexia and said any re-touched photo that alters the bodily appearance of a model for commercial purposes must carry a message stating it had been manipulated. “The activity of model is banned for any person whose Body Mass Index (BMI) is lower than levels proposed by health authorities and decreed by the ministers of health and labor,” the legislation says. The lawmaker behind the bill previously said models would have to present a medical certificate showing a BMI of at least 18, about 55 kg (121 lb) for a height of 1.75 meters (5.7 feet), before being hired for a job and for a few weeks afterwards. The law, voted through the lower house of parliament by Hollande’s Socialist majority despite opposition by conservative parliamentarians, envisages imprisonment of up to six months and a fine of 75,000 euros ($82,000) for any agency contravening it. A second measure means that any website inciting a reader to “seek excessive thinness by encouraging eating restrictions for a prolonged period of time, resulting in risk of mortality or damage to health” will face up to a year in prison and fines of up to 100,000 euros. Elite and IMG, two big modeling agencies present in France, both declined to comment on the moves. Some 30,000-40,000 people in France suffer from anorexia, most of them teenagers, health experts estimate. In 2010, Isabelle Caro, an anorexic 28-year-old former French fashion model, died after posing for a photographic campaign to raise awareness about the illness. Claim: France bans super-skinny models in anorexia clampdown.

Answer: France will ban excessively thin fashion models and expose modeling agents and the fashion houses that hire them to possible fines and even jail, under a new law passed on Friday.


Question: Paragraph: Brattleboro Retreat Board Chair Elizabeth Catlin said the organization is ready to work “with all willing partners” to help it achieve financial stability. The board began considering its options last week when the state of Vermont rejected a $2 million request for additional funding. “In recent years, the Brattleboro Retreat’s board and its management team have taken a number of creative, cost-conscious steps to reshape and modernize hospital operations while meeting the rising tide of soaring labor costs,” said Catlin’s statement. “The Brattleboro Retreat’s quality of care, even with these financial pressures, continues to be excellent.”   The facility serves more than half the people in Vermont who need psychiatric care and provides all of the child and adolescent psychiatric care in the state. It also provides addiction services including inpatient and outpatient rehabilitation, and treatment services for those who get Suboxone, a prescription medication used to treat opioid addictions. If it closes, the letter said that would mean finding services for 2,500 inpatients annually as well as filling new gaps for Suboxone treatment services, residential programs for children and meeting other critical health needs. On Sunday, Vermont Human Services Secretary Michael Smith said he had rejected a request for an additional $2 million in funding from the retreat. That request would be added to a financial package valued at an estimated $16 million for new beds and a recent rate increase valued at an estimated $3.5 million per year. Smith said he rejected the request in part because he believes it would constitute a taxpayer bailout of financial miscalculations by Brattleboro Retreat’s management. But Josephson said the state wasn’t paying it enough to care for the patients the state wants cared for. On Friday, Josephson sent a letter Friday to Smith and Gov. Phil Scott, a Republican, that said the facility cannot continue operating without more support from the state. He said the board had authorized him to begin planning for the sale or closure of the retreat “in the very near future.” Claim: Psych hospital’s financial woes won’t stop services, for now.

Answer: Officials at Vermont’s largest private psychiatric hospital said Monday they are dedicated to providing quality mental health care to patients amid the possibility of the facility shuttering or being forced into a sale.


Question: Paragraph: The story mentioned that it was expected that the drug reported on would cost $8/day as compared with <$1/day for warfarin. One aspect of costs that were not considered in this story is the difference in monitoring, which would be less with patients using Eliquis. The competing HealthDay story did a better job on this latter point. The story provided only relative risk reduction figures – “prevented 21 percent more strokes…31 percent fewer incidents of major bleeding…reduced total deaths by 11 percent” – but neglected to present the absolute decrease in adverse events. 21% of what? 31% of what? 11% of what? The story mentioned some of the disadvantages associated with this use of the medication reported on. It did not specifically detail whether there were any harms associated with this medication or how well people in the study were able to stick with the dosing schedule. On this issue, this story was not as complete as its HealthDay competition, which reported: “The new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns. In that trial, published in July in the New England Journal of Medicine, apixaban’s use was associated with raised odds for bleeding — without providing patients with any reduction in heart attack risk.However, “in that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,” Ansell noted. “The three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population. But, that’s an entirely different problem, compared with atrial fibrillation,” he said.” The story included a lot of information about the study it reported on – where the results were presented and published, its design, the number of clinical sites, countries involved, the number of people studied and the length of time they were studied.. No overt disease mongering. The story mentioned that the study reported on had been funded by the drug maker. It included comments from a clinician who had no ties to the study reported on. The story compared the study drug with the long time treatment, warfarin, as well as mentioning a newly approved medication and another medication in the approval process. The story opened by indicating that Eliquis (apixabane) was experimental and closed by indicating the expectation of submission to the FDA for approval. The story was clear that this was a new medication, though there are two other medications (warfarin and Pradax) that are currently available. Did not appear to rely solely on a news release. Claim: Trial Shows Blockbuster Potential for Blood Clot Pill

Answer:
This is a story about a large clinical trial that found a new medication to be more effective though more expensive than the current medication used to reduce the chance of blood clot formation in individuals with atrial fibrillation. The story did a good job of detailing the study reported on as well as the financial ramifications for the drug maker. It remains to be seen whether the adherence seen in the trial will be as good in the real world. And Eliquis, the drug reported, still needs to undergo review by the FDA for safety and efficacy. But it appears that at least some clinicians and market analysts are enthused about the impact of this medication. A drawback of this story is that it fails to provide information about the absolute reduction in risks that may be possible with this medication. In the absence of this information, it is impossible to assess the true scope of how valuable a treatment this might be. The risk of hemorrhagic stroke is a concern to those who use warfarin as part of their treatment for atrial fibrillation. The availability of a medication that reduces that risk and is a more effective treatment for their condition will be of interest to those who can afford the added costs.